Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica - 13/01/23
![](/templates/common/images/mail.png)
Abstract |
Cancer is currently the most important problem endangering human health. As antitumor drugs have always been the most common methods for treating cancers, searching for new antitumor agents is of great significance. Brusatol, a quassinoid from the seeds of Brucea javanica, exhibits a potent tumor-suppressing effect with improved disease outcome. Studies have shown that brusatol not only shows potential tumor inhibition through multiple pharmacological effects, such as promoting apoptosis and inhibiting metastasis but also exhibits significant synergistic antitumor effects in combination with chemotherapeutic agents and overcoming chemical resistance in a wide range of cancer types. In this paper, the antitumor effects and mechanisms of brusatol were reviewed to provide evidence that brusatol has the exact antitumor efficacy of chemotherapeutic agents and show the potential of brusatol to be developed as a promising antitumor drug.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
As a particularly noteworthy bioactive constituent of Brucea javanica, Brusatol shows potential tumor inhibition and significant synergistic antitumor effects in cancer therapy.
As a particularly noteworthy bioactive constituent of Brucea javanica, Brusatol shows potential tumor inhibition and significant synergistic antitumor effects in cancer therapy.ga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | Brusatol is a potential antitumor constituent from Brucea javanica. |
• | Brusatol is a potent Nrf2 inhibitor for future cancer treatment. |
• | Brusatol exhibits significant tumor inhibition in multiple cancers. |
• | Brusatol exerts synergistic antitumor activity in various cancers. |
• | Brusatol is a promising sensitizing agent for cancer therapy. |
Keywords : Brusatol, Nrf2 inhibitor, Apoptosis, Synergistic antitumor effect, Molecular mechanism
Plan
Vol 158
Article 114134- février 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?